Opinion

Video

What’s new in the latest edition of “Dr. Patrick Walsh’s Guide to Surviving Prostate Cancer”

"It was really wonderful to work with a lot of our coauthors for the chapters because they really are thought leaders in the field," says Edward M. Schaeffer, MD, PhD.

In this video, Edward M. Schaeffer, MD, PhD, discusses what’s new in the latest edition of the book “Dr. Patrick Walsh’s Guide to Surviving Prostate Cancer.” Schaeffer is chair and Harold Binstein Professor of Urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Transcription:

About one third of the book is all new. What's new are specific chapters that are on various components of the disease state. First, we created a new chapter that really talks and specifically focuses on genetics and risk and so forth. We also created a chapter on survivorship. Survivorship has always historically been focused on individuals with more advanced stage cancers, and I learned from my patients that survivorship often begins at the initial diagnosis. So survivorship is really surviving and working through and championing through a diagnosis. And that's not at the very end, but should really begin at the beginning. We wrote a new specific chapter on understanding and really mapping out unique needs for gay and bisexual men with prostate cancer, which I've known for a long time was historically a deficiency in my personal practice, and knew for a long time, if it was a deficiency in my practice, many providers out there were probably not properly servicing this community. And therefore, we wrote a chapter with one of my partners, Dr. Channa Amarasekera, who leads the field in this area. He opened the first-in-class clinic in the country dedicated to these types of men. It was exciting to write a chapter with him. Also, within the advanced prostate cancer space, there have been a tremendous number of advances for these individuals. And so we created a whole new chapter on all the new therapies, lots of new compounds that have been approved, molecular imaging-based compounds, out-of-the-box stuff that just wasn't on the roadmap 5 or 6 years ago when the last edition was written. So that was super great. And then all the existing chapters, we've refined with new cutting-edge learnings, and so that's also been fun to do. So it was a great book, with lots of opportunities for myself to learn about the disease and refine how to think about it and communicate it to patients. And then it was really wonderful to work with a lot of our coauthors for the chapters because they really are thought leaders in the field.

This transcript was edited for clarity.

Related Videos
Ravi Munver, MD, answers a question during a Zoom video interview
1 KOL is featured in this series.
1 KOL is featured in this series.
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Woman having telemedicine appointment with doctor | Image Credit: © Jacob Lund - stock.adobe.com
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Related Content
© 2024 MJH Life Sciences

All rights reserved.